Is it time to offer BRCA1 and BRCA2 testing to all jewish women?

Current Oncology

Volumn 22, Issue 4, 2015, Pages e233-e236

  Metcalfe, K A ^a,b   Eisen, A ^c,d   Lerner Ellis, J ^e   Narod, S A ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^d CANCER CARE ONTARIO   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84939604539     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.22.2527     Document Type: Note

References (18)

1. Metcalfe KA, Poll A, Royer R, et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 2010;28:387–91.
2. Gabai-Kapara E, Lahad A, Kaufman B, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S A 2014;111:14205–10.
3. Manchanda R, Loggenberg K, Sanderson S, et al. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. J Natl Cancer Inst 2015;107:379.
4. King MC, Levy-Lahad E, Lahad A. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA 2014;312:1091–2.
5. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401–8.
6. Roa BB, Boyd AA, Vocik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185–7.
7. Metcalfe KA, Poll A, Royer R, et al. A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testing. Br J Cancer 2013;109:777–9.
8. Manchanda R, Legood R, Burnell M, et al. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing. J Natl Cancer Inst 2015;107:380.
9. Metcalfe KA, Poll A, Llacuachaqui M, et al. Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2. Clin Genet 2010;78:411–17.
10. Schwartz MD, Peshkin BN, Hughes C, Main D, Isaacs C, Lerman C. Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol 2002;20:514–20.
11. Watson M, Foster C, Eeles R, et al. on behalf of the Psychosocial Study Collaborators. Psychosocial impact of breast/ ovarian (BRCA1/2) cancer–predictive genetic testing in a UK multi-centre clinical cohort. Br J Cancer 2004;91:1787–94.
12. Smith AW, Dougall AL, Posluszny DM, Somers TJ, Rubinstein WS, Baum A. Psychological distress and quality of life associated with genetic testing for breast cancer risk. Psychooncology 2008;17:767–73.
13. Meiser B, Butow P, Friedlander M, et al. Intention to undergo prophylactic bilateral mastectomy in women with an increased risk of developing hereditary breast cancer. J Clin Oncol 2000;18:2250–7.
14. Metcalfe KA, Mian N, Enmore M, et al. Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening. Breast Cancer Res Treat 2012;133:735–40.
15. Antoniou AC, Pharoah PD, Narod S, et al. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 2005;42:602–3.
16. Finkelman BS, Rubinstein WS, Friedman S, et al. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol 2012;30:1321–8.
17. Metcalfe K, Lubinski J, Lynch HT, et al. on behalf of the Hereditary Breast Cancer Clinical Study Group. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. J Natl Cancer Inst 2010;102:1874–8.
18. Finch AP, Lubinski J, Moller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014;32:1547–53.